SUMMARY We compared the antianginal efficacy of one conventional and three long acting beta-adrenoreceptor blocking agents in a randomised manner in 12 patients with stable angina pectoris. An exercise test was performed initially and in the 24th hour after a single daily dose of 160 mg of each beta-blocker at the end of a two week treatment period. In addition, glyceryl trinitrate consumption, anginal attack rate, and activity scores were recorded. No titration studies to an equivalent degree of beta-blockade were undertaken; a fixed dose was used even though these drugs are not equipotent.
Conventional beta-adrenoreceptor blocking drugs are given divided into three or four daily doses because of their short serum half-life. Recently, various long acting preparations have been introduced with the expectation that a single daily dose would provide a sustained antianginal-effect, ensure 24 hour betaadrenoreceptor blockade, and achieve improved patient compliance. So far no clinical study has shown any improvement in the antianginal effect of a divided dose regimen, as compared with the same dose taken on a single once-daily basis. It also remains to be established that the antianginal effect of a long acting beta-adrenoreceptor blocking drug extends its antianginal efficiency to the 24th hour before the next dose is due.
This study was undertaken to compare four betaadrenoreceptor drugs for their antianginal efficiency in the 24th hour after a single daily dose treatment period. Propranolol was used to represent a convenReceived for publication 26 May 1981 tional beta-adrenoreceptor blocker: the three other preparations were chosen because in each case the mechanism for a prolonged serum half-life was different.
Patients and methods

PATIENTS
Twelve patients with an average age of 56 years (range 39 to 71) with stable angina pectoris were studied. In all of these carefully selected patients, angina could be reproduced during bicycle (ergometer) exercise and in all cases ST depression of more than 1 mm for 0-8 s duration on V5 developed. None of the patients had any evidence of heart failure. Eleven patients had been taking a beta-adrenoreceptor blocking drug for more than six months and the twelfth patient was started on long acting propranolol six weeks before his entry into this study. The dose of the drug in each was 160 mg either in divided doses or as a long acting 503 The exercise procedure was essentially in accordance with the one designed by Redwood et al. 6 All patients were brought to the exercise laboratory (temperature 200 to 24°C) on at least three weekly occasions before the definitive studies. They exercised upright on a bicycle ergometer (Monark, Sweden) and pedalled steadily in time with a metronome at 50 rpm. The exercise capacity was assessed by increasing the work load by 300 kilopondmetres (kpm) every four minutes until the onset of angina. The heart rate was monitored continuously through a V5 lead. Each patient was entered into the study after the anginal point had become reproducible. On the day of the definitive test, the patients were studied in the morning after 30 minutes rest, and asked not to take any glyceryl trinitrate (GTN) on that day. Each patient was exercised exactly 23 hours after the last dose of a beta-adrenoreceptor blocker. At the point of onset of angina the total exercise load, duration of exercise, and heart rate were recorded. A 12 lead electrocardiogram was taken before and within two minutes of the exercise. ST segment depression in all leads (:ST) was documented. This exercise procedure was carried out at the entry of a patient into the study, at each cross over point, and at the end of the study.
Four beta-adrenoreceptor blocking agents, conventional propranolol, long acting propranolol, sustained release oxprenolol, and nadolol were studied. Propranolol was chosen as a conventional betaadrenoreceptor blocking drug with a short serum half-life. The three long acting preparations achieve a long serum half-life by different mechanisms: long acting propranolol allows slow diffusing of the active drug from microspheres, in slow release oxprenolol, oxprenolol is leached out of a polymer colander, and nadolol has an intrinsically long plasma half-life, being slowly excreted. 
Results
ANTIANGINAL EFFICIENCY
The glyceryl trinitrate consumption and anginal attack rate were lowest during the nadolol period of two weeks (Table 2) . Patients were able to increase their activity either at home, at work, or socially during the nadolol and long acting propranolol periods. The score for these activities was better during nadolol and long acting propranolol, as compared with pretrial and conventional propranolol periods ( Table 1 ). The sense of well-being was not easy to define, but the patients complained that though the anginal frequency was not significantly different between various periods, the attacks tended to occur in clusters in the evening and early morning during conventional propranolol and slow release oxprenolol as opposed to long acting propranolol and nadolol periods.
EXERCISE PERFORMANCE
The maximal exercise performance to the point of angina was not significantly different between propranolol, long acting propranolol, and nadolol ( Fig.  1 ), but the mean kpm achieved was lowest during slow release oxprenolol and highest during nadolol. Interestingly, 23 hours after a single dose of conventional propranolol, the exercise performance was as good as long acting propranolol and better than slow release oxprenolol.
The mean resting heart rate 23 hours after the last dose of nadolol was significantly lower (p<0 05) at 57±4 bpm (SEM) than with slow release oxprenolol and conventional propranolol (Fig. 2) . The mean resting pulse rate was 63±4 bpm during long acting propranolol, 70±4 bpm during slow release oxprenolol, and 71±6 bpm during conventional propranolol. There was no significant difference between these three. The exercise-induced tachycardia at the anginal point was lowest after nadolol (93 bpm) and the difference between nadolol and the two other long acting beta-blockers was highly significant (p<00 1). The two long acting formulations, slow release oxprenolol and long acting propranolol, also showed a significant reduction in exercise induced tachycardia as compared with conventional propranolol). The mean heart rate at the onset of angina was 115±4 bpm after slow release oxprenolol, 107±3 bpm after long acting propranolol, and 130±4 bpm after conventional propranolol. (Fig. 3) . ' ST depression was significantly lower (p<005) after nadolol as compared with the other three preparations.
SIDE EFFECTS
Bradycardia after nadolol did not produce any symptoms. One patient on nadolol and one on conventional propranolol complained of cold hands and feet and numbness. There was no objective evidence of peripheral neuropathy, and electromyographic studies showed no conduction impairment.
PLASMA CONCENTRATION
The mean plasma drug concentration was highest in the 24th hour after nadolol (134-6±14-4 SEM) and lowest at 13±4 ng/ml after conventional propranolol. The high serum level of nadolol was in keeping with a significant reduction in the simultaneously studied exercise-induced tachycardia (Fig. 2) , but it is of interest to note that the low level of conventional propranolol was also accompanied by a lower exercise heart rate than would be expected without betablockade. Long acting propranolol and slow-release oxprenolol occupied intermediate places with the 24th hour mean plasma levels of 26 and 46 ng/ml, respectively. The drug was undetectable in the plasma of four patients in the slow release oxprenolol group, one in the conventional propranolol group, and one in the long acting propranolol group.
Discussion
This study showed that there was no significant difference in the frequency of anginal attacks and glyceryl trinitrate consumption between the treatment periods. The overall patient preference was in favour of long acting propranolol and nadolol (Table 1) ; the patients felt better subjectively, the anginal attacks did not occur in clusters towards the evenings and early mornings (as happened with conventional propranolol and slow release oxprenolol), they were able to lead a more active life, and, with nadolol, the anginal attack rate as well as the glyceryl trinitrate consumption were less than with the other three drugs (Table 2 ). An interesting finding was that a single dose of conventional propranolol was as effective in controlling the frequency of angina as long acting formulations of propranolol and oxprenolol. The mean propranolol level in the 24th hour was 13±4 ng/ml, which is capable of producing a significant beta-blockade.4 5 Though plasma levels of slow release oxprenolol were higher than conventional propranolol, a lower work load was achieved during the former. Other workers' data" suggest that dose for dose propranolol is slightly more effective in angina than oxprenolol and that nadolol is more potent than propranolol.8
The absorption of slow release oxprenolol may be erratic from the gut since four of the 12 patients had no oxprenolol in their plasma in the 24th hour. As slow release oxprenolol was the mainstay of their treatment during a period in which they experienced an increased frequency of anginal attack, and since the final tablet count failed to suggest a lack of compliance, it seems likely that either the drug was not absorbed, or, for some reason, was rapidly excreted in these four patients.
Nadolol is a newly introduced beta-blocker with a long serum half-life of 16 to 24 hours.7 This study showed that it maintained high plasma levels in the 24th hour after a single daily dose treatment and produced a highly significant degree of beta-blockade as shown by suppression of exercise induced tachycardia compared with slow release oxprenolol and long acting propranolol. The post-exercise " ST segment depression was significantly lower than with the other three preparations.
Our studies indicate that when given as a single dose the antianginal efficacy in the 24th hour relates to the degree of beta-adrenoreceptor blockade achieved at that time, and 160 mg nadolol was the most effective and 160 mg slow release oxprenolol the least effective in achieving this. 
